Baxter International (BAX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 May, 2026Opening remarks and agenda
Meeting conducted via webcast for safety and convenience, with technical support available.
Agenda and matters to be considered were distributed to all stockholders.
Five items of business were scheduled for voting, with Q&A to follow if time permitted.
Board and executive committee updates
Board members introduced, including a new director, Mike McDonnell.
Retirements and resignations of Dr. Stephen Oesterle, Cathy Smith, and Stephen Rusckowski acknowledged.
Corporate governance
Quorum established with majority of 516 million shares represented.
Inspector of Elections and independent auditor present; auditor available for Q&A.
Voting procedures and proxy rules explained, with opportunity to change votes during the meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Baxter International
- Strategic transformation, innovation, and new launches drive growth and margin expansion.BAX
Raymond James 46th Annual Institutional Investors Conference9 Jul 2026 - Exceeded 2024 guidance, completed major divestiture, and forecasts robust 2025 growth.BAX
Q4 20248 Jul 2026 - Q2 2025 sales and EPS rose, guidance maintained, and debt reduced amid ongoing industry risks.BAX
Q2 20258 Jul 2026 - Q3 sales up 4%, adjusted EPS beat guidance; hurricane and Kidney Care sale drive major changes.BAX
Q3 20248 Jul 2026 - Stabilization, margin expansion, and capital flexibility set the stage for renewed growth in 2025.BAX
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Transformation focuses on accountability, margin expansion, and capital allocation flexibility.BAX
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 sales up 3% reported, adjusted EPS down 35%, full-year outlook reiterated.BAX
Q1 202630 Apr 2026 - Proposal to amend Board size parameters aims to enhance flexibility and governance.BAX
Proxy filing29 Apr 2026 - Q4 sales up 8% but adjusted EPS down 24%; 2026 outlook flat with margin recovery expected.BAX
Q4 202512 Apr 2026